Its expression leads to a functional insufficiency in HR which is mediated through inhibition of the BRCA2 tumor suppressor, and subsequently a high sensitivity to small-molecule inhibitors of Poly (ADP-ribose) polymerase 1 (PARP1). Here, PARP1 is linked to neoplasm.